Advertisement

Tobramycin Injection

[21 November 2016]

Products Affected - Description

Tobramycin Sulfate solution for injection, Akorn
40 mg/mL, 2 mL vial, 25 count (NDC 17478-0114-02)
40 mg/mL, 30 mL vial, 1 count (NDC 17478-0114-30)
 
Tobramycin Sulfate solution for injection, Hospira
10 mg/mL, 2 mL vial, 25 count (NDC 00409-3577-01) - discontinued
40 mg/mL, 50 mL vial, 1 count (NDC 00409-3590-02) - discontinued
80 mg/100 mL, premixed bag, 24 count (NDC 00409-3470-23 - discontinued
 
Tobramycin Sulfate solution for injection, Mylan Institutional
40 mg/mL, 30 mL vial, 10 count (NDC 67457-0428-30)
 
Tobramycin Sulfate solution for injection, Teva
40 mg/mL, 2 mL vial, 25 count (NDC 00703-9402-04)
40 mg/mL, 30 mL vial, 1 count (NDC 00703-9416-01)

Reason for the Shortage

  • Akorn has recently launched tobramycin solution for injection.
  • Fresenius Kabi has tobramycin solution for injection on shortage due to increased demand.
  • Mylan Institutional could not provide a reason for the shortage.
  • Teva has tobramycin solution for injection on shortage due to manufacturing delays.

Available Products

Tobramycin Sulfate lyophilized powder for solution for injection, Fresenius Kabi
1.2 gram, 50 mL preservative-free vial, 6 count (NDC 63323-0303-51)
 
Tobramycin solution for injection, Fresenius Kabi
10 mg/mL, 2 mL vial, 25 count (NDC 63323-0305-02)
40 mg/mL, 2 mL vial, 25 count (NDC 63323-0306-02)
40 mg/mL, 30 mL vial, 10 count (NDC 63323-0306-30)
40 mg/mL, 50 mL vial, 1 count (NDC 63323-0307-51)
 
Tobramycin Sulfate solution for injection, Hospira
40 mg/mL, 2 mL vial, 25 count (NDC 00409-3578-01)
 
Tobramycin Sulfate solution for injection, Mylan Institutional
40 mg/mL, 2 mL vial, 25 count (NDC 67457-0473-22)
 
Tobramycin Sulfate lyophilized powder for solution for injection, X-Gen
1.2 gram, 50 mL preservative-free vial, 1 count (NDC 39822-0412-01)
1.2 gram, 50 mL preservative-free vial, 6 count (NDC 39822-0412-06)

Estimated Resupply Dates

  • Akorn has tobramycin 40 mg/mL 30 mL vials on back order and the company estimates a release date of early-December 2016. The 40 mg/mL 20 mL vials are on back order and the company cannot estimate a release date.
  • Teva has tobramycin 40 mg/mL solution for injection on long term back order and the company estimates a release date of November 2016.
  • Mylan Institutional has tobramycin 40 mg/mL 30 mL vials on back order and the company estimates a release date of late-November 2016.

Related Shortages

Updated

November 21 and 10, September 20 and 7, August 16, 9 and 8, June 28, May 24, April 6, March 21, February 22, January 14, 2016; December 21, November 4, October 28, September 24 and 4, August 20, June 15, May 18, April 3, February 27, January 22, 2015; December 12, October 24, September 24, August 28, July 31, June 12, April 11, February 27, January 24, 2014; December 10, November 19, October 24, August 27, July 30, June 19, May 17, April 29, March 20, February 25, January 16, 2013; December 3, November 14, September 17, August 2, July 25, April 17, March 21, February 29, January 18, 2012; December 21, November 2, October 29, August 26, July 28 , June 24, May 17, April 20, March 10, February 17, 2011; December 21, November 8, September 30, August 18, July 22, June 30, May 28, 2010, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement
ASHP Product Listing